Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

CONCLUSIONS: Consistent with findings in the overall population, abemaciclib plus NSAI was an effective initial treatment in the Japanese subpopulation, with a manageable safety profile.CLINICAL TRIAL REGISTRATION: NCT02246621; U.S. National Library of Medicine: https://clinicaltrials.gov/ct2/show/NCT02246621 .PMID:34661821 | DOI:10.1007/s12282-021-01295-0

Source: Breast Cancer - October 18, 2021 Category: Cancer & Oncology Authors: Masato Takahashi Eriko Tokunaga Joji Mori Yoshinori Tanizawa Jan-Stefan van der Walt Tsutomu Kawaguchi Matthew P Goetz Masakazu Toi Source Type: research